US sets policy to seize patents of government-funded drugs if price deemed too high
Isabelle Lawler, a pharmacy student, answers calls at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., February 26, 2021. Picture taken February...
archiveGENHLT
HSBC apologises as thousands of UK customers locked out of digital banking
A man speaks on a mobile phone in front of the head office of HSBC bank in Mumbai November 20,...
Trump plans sweeping undocumented immigrant roundups, detention camps, New York Times reports
Republican presidential candidate and former U.S. President Donald Trump attends a campaign rally in Claremont, New Hampshire, U.S., November 11,...
Novo Nordisk invests $6 bln in Wegovy production, still far below demand -CEO
The logo of Danish drugmaker Novo Nordisk, Copenhagen, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo Acquire Licensing RightsLONDON/COPENHAGEN, Nov 10 (Reuters) - Obesity drug maker Novo Nordisk (NOVOb.CO) said on Friday it will spend $6 billion to boost production in Denmark, although its chief executive warned the industry was far from being able to produce enough weight-loss drugs to meet global demand.Novo Nordisk has had phenomenal success with its anti-obesity drug, Wegovy, but has scrambled to address shortages that have forced it to limit the number of patients.The World Health...
EU approves Pfizer’s RSV vaccine to protect infants and older adults
A company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo Acquire Licensing...
Pfizer, BioNTech propose EU pays half for each cancelled COVID dose, Financial Times reports
April 30 (Reuters) - Pfizer Inc (PFE.N) and BioNTech's (22UAy.DE) new proposal to the European Union, amid a glut of...
Novo obesity drug to launch in the UK soon, says watchdog
LONDON, March 8 (Reuters) - Novo Nordisk's (NOVOb.CO) keenly anticipated weight loss medicine, Wegovy, will soon be made available to...
Why Europe’s drug shortages may get worse
Most European countries reporting shortages of antibioticsLow generic drug prices mean razor-thin margins for firmsCompanies say they cannot boost output...
